Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
PHASE1
This phase I trial tests the safety, side effects and best dose of BAY 1895...
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
PHASE1
This phase I trial investigates the best dose, possible benefits and/or sid...
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
PHASE1
This phase I trial identifies the best dose, possible benefits and/or side ...
Status
Active Not Recruiting
Location
National Cancer Institute Developmental Therapeutics Clinic
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
PHASE1
This phase I trial evaluates the best dose, possible benefits and/or side e...
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
PHASE1
This phase I trial identifies the best dose, possible benefits and/or side ...
Status
Active Not Recruiting
Location
University of California Davis Comprehensive Cancer Center
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
PHASE1
The purpose of the study is to test how well patients with advanced solid t...